Immune checkpoint molecules play a pivotal role in the initiation, regulation, and termination
of immune responses. Tumor cells exploit these checkpoints to dampen immune cell …

Melanoma, a highly aggressive skin cancer, is characterized by rapid progression and high
mortality. Recent advances in molecular pathogenesis have shed light on genetic and …

Simple Summary Precision oncology is emerging as a viable option to improve survival in
patients who fail to remain disease-free even after the employment of currently available …

Relatlimab is a type of human immunoglobulin G4 monoclonal blocking antibody. It is the
world's first Lymphocyte-Activation Gene-3 (LAG-3) inhibitor and the third immune …

Stage III unresectable and stage IV melanoma (also known together as 'advanced
melanoma') is nowadays the realm of the medical oncologist rather than the surgical …

In recent years, there have been notable advancements in the field of cancer
immunotherapy, namely in the area of immune checkpoint inhibition. The Lymphocyte …

The advent of immune checkpoint inhibitors and combination therapy with BRAF inhibitors
and MEK inhibitors has dramatically improved the prognosis of advanced melanoma …

Melanoma accounts for a minority of cutaneous malignancies, but it is related to most deaths
of skin cancers [1 2]. The treatment landscape in the metastatic setting has recently …

Gastric cancer (GC) is a malignant neoplasm originating from the epithelial cells of the
gastric mucosa. The pathogenesis of GC is intricately linked to the tumor microenvironment …

Lymphocyte activation gene 3 (LAG-3) has attracted much attention as a potentially valuable
immune checkpoint. Individual identification of LAG-3 expression at screening and during …